Clever Culture Systems (CC5) Q2 2026 earnings summary

Executive summary

• Three new APAS® Independence sales orders received, increasing the installed base to 27 instruments globally, with AstraZeneca now at 11 units.

• Annual recurring revenues surpassed $1.0 million, driven by AI software licenses and maintenance services.

• Net cash inflows of $1.7 million for the quarter, with all debt repaid and a cash balance of $3.1 million at quarter end.

• Major pharma customers, including AstraZeneca, Bristol Myers Squibb, and Pfizer, presented positive data on APAS® at global conferences.

Financial highlights

• Receipts from customers totaled $1.84 million for the quarter.

• Net cash inflows from operating and investing activities were $0.6 million; financing activities contributed $1.1 million.

• Cash outflows included $0.6 million for instrument parts and $0.3 million for sales-related expenses.

• $1.1 million received from the FY25 R&D Tax Incentive.

• All debt, including a $975,000 government loan, was fully repaid.

Outlook and guidance

• Focus remains on expanding sales with top-20 pharma companies, targeting multiple placements within customer groups.

• Expected cash inflows of at least $1.9 million over the next two quarters from receivables and committed sales.

• Additional sales and placements anticipated in the next six months to broaden the APAS® user base.